Skip to main content

Day: October 20, 2025

FERRARI RENEWS ITS COLLABORATION WITH BITDEFENDER

Maranello (Italy), October 20, 2025 – Ferrari N.V. (NYSE/MTA: RACE) (“Ferrari” or “the Company”) announced today that its wholly-owned Italian subsidiary, Ferrari S.p.A., has renewed its multi-year partnership with Bitdefender, a global leader in cybersecurity. For further information:Media Relationstel.: +39 0536 949337Email: media@ferrari.comAttachmentFNV_Bitdefender_ENG

Continue reading

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. As part of the conference, members of management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the Company’s Maxim Growth Summit presentation slide deck, please visit the Presentations page on aimimmuno.com. For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit. About...

Continue reading

Kartoon Studios Announces $7.3 Million Financing Priced at Market with Single Institutional Investor

Capital infusion fuels the global launch of Winnie & Friends, the Stan Lee Universe expansion, and the Bitcoin Brigade rollout Investment validates Kartoon Studios’ strategic direction BEVERLY HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) — Kartoon Studios, Inc. (NYSE American: TOON) (the “Company”), a leading global producer and distributor of premium children’s and family entertainment, today announced it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of approximately $7.3 million of equity in the Company. The closing of the Offering is expected to occur on or about October 22, 2025, subject to the satisfaction of customary closing conditions, including approval by NYSE American. The gross proceeds from the Offering are expected to be approximately $7.3 million...

Continue reading

24/7 Market News: VENU Positioned to Capitalize on $408.5B Music Event Market Growth

Sunset Amphitheater Momentum and $5B Pipeline Plan Accelerate VENU’s National Rollout DENVER, Oct. 20, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reaffirms VENU’s (NYSE American: VENU), a growing operator of premium hospitality and live entertainment venues across the U.S., unique market position, as new data from Zion Market Research forecasts the global music event industry to more than double in size, from $164.85 billion in 2024 to $408.54 billion by 2034, at a projected CAGR of 9.5%. As the sector undergoes rapid transformation fueled by digital innovation, hybrid events, immersive experiences, and the post-pandemic surge in demand, VENU is scaling rapidly with a development pipeline, premium product sales, and...

Continue reading

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU

         EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU Lyon, France – October 20, 2025 – EDAP TMS SA (Nasdaq: EDAP) (“EDAP” or the “Company”), a global leader in robotic, energy-based therapeutic technologies, today announced that it has entered into a €36 million multi-tranche credit facility (the “Credit Facility”) with the European Investment Bank (the “EIB”). Proceeds from the financing will be used to support the continued global expansion of the Company’s Focal One Robotic High-Intensity Focused Ultrasound (HIFU) platform. The funds will also accelerate the development of new clinical indications for the Company’s innovative HIFU technology. EDAP expects to draw the first tranche of €11 million under the Credit Facility in the fourth quarter of 2025. “This...

Continue reading

HUHUTECH International Group Inc. Launches Singapore Subsidiary to Advance Global Market Expansion

Wuxi, China, Oct. 20, 2025 (GLOBE NEWSWIRE) — HUHUTECH International Group Inc. (Nasdaq: HUHU) (the “Company” or “HUHUTECH”), a professional provider of factory facility management and monitoring systems, today announced that on August 6, 2025, it established a wholly owned subsidiary, HUHU TECHNOLOGY SINGAPORE PTE. LTD. (“HUHU Singapore”), in Singapore. The establishment of the subsidiary represents another significant move in the Company’s global expansion strategy, strengthening its presence in Asia. HUHU Singapore aims to drive market development for the Company’s system integration solutions in the Singaporean market, with a focus on delivering high-purity gas supply systems to local pan-semiconductor industry customers. It plans to provide comprehensive, localized services ranging from system design to maintenance and after-sales...

Continue reading

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) —  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role, Mr. Atkisson will oversee Achieve’s legal strategy, corporate governance, compliance, and risk management. “Erik’s extensive legal, regulatory and M&A background in the biopharmaceutical sector provides valuable experience as we advance cytisinicline through regulatory review and prepare for a potential launch,”...

Continue reading

SGBX Subsidiary Olenox Energy Announces an Aggressive Drilling Agenda Slated to Begin Q4 2025 and Expand Throughout 2026

CONROE, Texas, Oct. 20, 2025 (GLOBE NEWSWIRE) — via IBN – Olenox Corp, a vertically integrated energy company and wholly owned subsidiary of  Safe & Green Holdings Corp. (NASDAQ: SGBX), is pleased to announce Olenox has begun the initial review of several drilling sites on current leases held within its oil and gas portfolio. As the energy development arm of SGBX, Olenox intends to implement an aggressive drilling program with plans to target completion of one drilling project during the fourth quarter of 2025, followed by an ambitious drilling agenda outlined for 2026 and beyond. “While we are still bringing on legacy production on our leases, the company is committed to generate new production through an aggressive drilling program to meet our internal goal of 1,000 BOE a day by the end of 2026,” said Michael McLaren, CEO...

Continue reading

Gaia Sets Third Quarter 2025 Conference Call for Monday, November 3, 2025, at 4:30 p.m. ET

BOULDER, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA) – the world’s largest streaming and community platform dedicated to, personal transformation, health, wellness, and spirituality – will conduct a conference call on Monday, November 3, 2025, at 4:30 p.m. Eastern time (2:30 p.m. Mountain time) to discuss its financial results for the third quarter ended September 30, 2025. The company will report its financial results in a press release prior to the call. Gaia management will host the conference call, followed by a question and answer period. Date: Monday, November 3, 2025Time: 4:30 p.m. Eastern time (2:30 p.m. Mountain time)Toll-free dial-in number: 1-877-269-7751International dial-in number: 1-201-389-0908Conference ID: 13756365 Please call the conference telephone number 5-10 minutes prior to the...

Continue reading

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the expiration at 5pm EST of 53,147 warrants (originally 3,454,543 warrants issued pre-reverse stock split (65 to 1)). All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represents the very last tranche of warrants issued to hedge funds and investment funds. Quantum BioPharma also re-iterates October 27, 2025 as the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.